Technical Analysis for IMCR - Immunocore Holdings plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 0.11% | |
| Wide Bands | Range Expansion | 0.11% | |
| Oversold Stochastic | Weakness | 0.11% | |
| Hammer Candlestick | Bullish | 7.61% | |
| MACD Bullish Signal Line Cross | Bullish | 7.61% | |
| Lizard Bullish | Bullish Day Trade Setup | 7.61% | |
| Doji - Bullish? | Reversal | 7.61% | |
| New 52 Week Low | Weakness | 7.61% | |
| Wide Bands | Range Expansion | 7.61% | |
| Oversold Stochastic | Weakness | 7.61% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 7 hours ago |
| Up 5% | about 8 hours ago |
| Rose Above 10 DMA | about 9 hours ago |
| 10 DMA Resistance | about 9 hours ago |
| 60 Minute Opening Range Breakout | about 9 hours ago |
Get a Trading Assistant
- Earnings date: 08/08/2024
Immunocore Holdings plc Description
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Infectious Diseases Autoimmune Disease Oncology Breast Cancer Virotherapy Immunotherapies Small Cell Lung Cancer Solid Tumor Cancers Oncolytics Biotech Treatment Of Autoimmune Disease Chronic Hepatitis B Virus Immunocore Pelareorep
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 76.98 |
| 52 Week Low | 33.045 |
| Average Volume | 876,802 |
| 200-Day Moving Average | 56.64 |
| 50-Day Moving Average | 48.45 |
| 20-Day Moving Average | 38.35 |
| 10-Day Moving Average | 35.33 |
| Average True Range | 1.84 |
| RSI (14) | 33.77 |
| ADX | 61.02 |
| +DI | 15.91 |
| -DI | 39.03 |
| Chandelier Exit (Long, 3 ATRs) | 43.53 |
| Chandelier Exit (Short, 3 ATRs) | 38.56 |
| Upper Bollinger Bands | 44.94 |
| Lower Bollinger Band | 31.77 |
| Percent B (%b) | 0.35 |
| BandWidth | 34.34 |
| MACD Line | -4.03 |
| MACD Signal Line | -4.31 |
| MACD Histogram | 0.282 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 40.41 | ||||
| Resistance 3 (R3) | 40.03 | 38.34 | 39.74 | ||
| Resistance 2 (R2) | 38.34 | 37.32 | 38.52 | 39.52 | |
| Resistance 1 (R1) | 37.38 | 36.70 | 37.86 | 37.76 | 39.30 |
| Pivot Point | 35.69 | 35.69 | 35.93 | 35.87 | 35.69 |
| Support 1 (S1) | 34.73 | 34.67 | 35.21 | 35.11 | 33.56 |
| Support 2 (S2) | 33.04 | 34.05 | 33.22 | 33.34 | |
| Support 3 (S3) | 32.08 | 33.04 | 33.12 | ||
| Support 4 (S4) | 32.46 |
